Therabel group strengthens partnership with Skyepharma Production

Skyepharma Production SAS, (“Skyepharma”) the contract development and manufacturing organization (CDMO) specialists in the development, manufacturing and packaging of classic and complex oral solid dosage forms, and Therabel, a privately-owned pharmaceutical group today announce their strengthened partnership for the production of Therabel’s solid form manufacturing.

Located in Saint-Quentin-Fallavier, in the greater Lyon area, near the international airport of Saint Exupery, the Skyepharma site provides solutions bringing value to its clients at any stage of a product’s development lifecycle, from small scale programs up to commercial manufacturing and packaging activities. Skyepharma’s value proposal includes tailored services to clients’ requirements supporting them up to market introduction for their solid dosage forms projects.

David Lescuyer, Executive Vice President, Vectura Group and President of Skyepharma Production S.A.S, added: “This agreement between Therabel and Skyepharma Production SAS is the result of a renewed partnership between both companies, and a strong reciprocal trust in how we work together.”

Therabel group is a privately-owned pharmaceutical company, with a European footprint. It is an organization which has achieved international expansion by means of both acquisitions and organic growth. Product portfolio is generated through collaborations with other pharmaceutical companies as well as its own proprietary portfolio. Thus, Therabel’s partnered products consistently benefit from the highest level of commitment, quality and focus.

Laurent Kirsch, C.O.O. of Therabel, added:” We are very pleased with the strengthening of our collaboration with Skyepharma while developing our solid forms manufacturing capabilities in Europe. We have particularly appreciated the robustness of Skyepharma team to implement fast integration as well as the state-of-the art equipment and project management processes”.